LOS ANGELES, CA--(Marketwired - February 13, 2014) - MediSwipe, Inc. (www.MediSwipe.com) (MWIP), the leader in Compassionate Care Technology Solutions and products for the medicinal marijuana industry, today announced that Goldman Small Cap Research, a stock market research firm, based out of Baltimore, Maryland and focused on the small cap and microcap sectors, has initiated research coverage of MediSwipe.
The medical marijuana and recreational marijuana industries are in the early innings of a major adoption phase which are expected to result in $20 billion in revenue in the coming years. Approved in 20 states and D.C., and with endorsements from high profile doctors such as Dr. Sanjay Gupta, more states will soon come on line increasing the size of the market.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"MediSwipe, which helped pioneer and design the use of a HIPAA-compliant back end record system, is the only pure play medical marijuana stock with a real presence in the critical payments and records segment of the industry. Targeting an estimated 75 million consumers, MediSwipe is a one-stop shop for medical marijuana needs for patients and physicians alike.
"In addition to its payments and record solutions, the Company sells popular hemp-based beverages and cutting-edge alternative tobacco products. The recently introduced Mont Blunt Vaporizer and other e-cig products could prove to be huge this year as well, with industry estimates calling for sales growing to $3 billion in 2015. With its peers trading at an average market cap around $200M, the overlooked MWIP has not yet made the big, inevitable run higher, which bodes well for new investors."
This press release contains excerpts of their most recently published sponsored article on MediSwipe, Inc. Goldman Small Cap Research sponsored articles, reports, and updates as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on their website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download their research, view their disclosures, or for more information, visit www.goldmanresearch.com.
About MediSwipe, Inc.
MediSwipe, Inc. (www.MediSwipe.com) provides innovative patient solutions and is the leader in Compassionate Care Technology for the medicinal marijuana industry. MediSwipe provides terminal-based service packages and integrated Web Portal add-ons for physicians, clinics, hospitals and medical dispensaries that include: digital patient records, Electronic Referrals, Credit/Debit Card merchant services, and health and wellness product lines including beverages, vaporizers and accessories.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of MediSwipe, Inc. to be materially different from the statements made herein.